Risperidone

Brand names: Risperdal · Active ingredient: Risperidone

In short: Risperidone oral solution is indicated for the treatment of schizophrenia. Efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults .

Forms & strengthsRisperidone oral solution is available in a 1 mg/mL strength.
LabelAtlantic Biologicals Corp.
Label updatedOct 21, 2026

What is Risperidone used for?

Risperidone oral solution is indicated for the treatment of schizophrenia. Efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults .

Monotherapy

Risperidone oral solution is indicated for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder. Efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) .

Adjunctive Therapy

Risperidone oral solution adjunctive therapy with lithium or valproate is indicated for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder. Efficacy was established in one short-term trial in adults .

Risperidone oral solution is indicated for the treatment of irritability associated with autistic disorder, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods. Efficacy was established in 3 short-term trials in children and adolescents (ages 5 to 17 years) .

âš  Boxed warning (FDA's strongest warning)

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.

Risperidone is not approved for the treatment of patients with dementia-related psychosis .

Risperidone dosage

Initial Dose | Titration (Increments) | Target Dose | Effective Dose Range

Schizophrenia: adults (

2.1) | 2 mg | 1 to 2 mg | 4 to 8 mg | 4 to 16 mg

Schizophrenia: adolescents (

2.1) | 0.5 mg | 0.5 to 1 mg | 3 mg | 1 to 6 mg

Bipolar mania: adults (

2.2) | 2 to 3 mg | 1 mg | 1 to 6 mg | 1 to 6 mg

Bipolar mania: children and adolescents (

2.2) | 0.5 mg | 0.5 to 1 mg | 1 to 2.5 mg | 1 to 6 mg

Irritability in autistic disorder (

2.3) | 0.25 mg Can increase to 0.5 mg by Day 4: (body weight less than 20 kg)

0.5 mg Can increase to 1 mg by Day 4: (body weight greater than or equal to 20 kg) | After Day 4, at intervals of > 2 weeks: 0.25 mg (body weight less than 20 kg)

0.5 mg (body weight greater than or equal to 20 kg) | 0.5 mg:

(body weight less than 20 kg)

1 mg:

(body weight greater than or equal to 20 kg) | 0.5 to 3 mg

Severe Renal and Hepatic Impairment in Adults: use a lower starting dose of 0.5 mg twice daily. May increase to dosages above 1.5 mg twice daily at intervals of one week or longer.

Adults

Usual Initial Dose

Risperidone oral solution can be administered once or twice daily. Initial dosing is 2 mg per day. May increase the dose at intervals of 24 hours or greater, in increments of 1 to 2 mg per day, as tolerated, to a recommended dose of 4 to 8 mg per day. In some patients, slower titration may be appropriate. Efficacy has been demonstrated in a range of 4 mg to 16 mg per day. However, doses above 6 mg per day for twice daily dosing were not demonstrated to be more efficacious than lower doses, were associated with more extrapyramidal symptoms and other adverse effects, and are generally not recommended. In a single study supporting once-daily dosing, the efficacy results were generally stronger for 8 mg than for 4 mg. The safety of doses above 16 mg per day has not been evaluated in clinical trials .

Adolescents

The initial dose is 0.5 mg once daily, administered as a single-daily dose in the morning or evening. The dose may be adjusted at intervals of 24 hours or greater, in increments of 0.5 mg or 1 mg per day, as tolerated, to a recommended dose of 3 mg per day. Although efficacy has been demonstrated in studies of adolescent patients with schizophrenia at doses between 1 mg to 6 mg per day, no additional benefit was observed above 3 mg per day, and higher doses were associated with more adverse events. Doses higher than 6 mg per day have not been studied.

Patients experiencing persistent somnolence may benefit from administering half the daily dose twice daily. …

How to take Risperidone — instructions & advice from the label

Advise patients using Risperidone oral solution to read the FDA-approved patient labeling (Instructions for Use) for Risperidone oral solution.

Physicians are advised to discuss the following issues with patients for whom they prescribe risperidone.

Neuroleptic Malignant Syndrome (NMS)

Counsel patients about a potentially fatal adverse reaction, Neuroleptic Malignant Syndrome (NMS), that has been reported in association with administration of antipsychotic drugs. Advise patients, family members, or caregivers to contact the healthcare provider or report to the emergency room if they experience signs and symptoms of NMS, including hyperpyrexia, muscle rigidity, altered mental status including delirium, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia) .

Tardive Dyskinesia

Counsel patients on the signs and symptoms of tardive dyskinesia and to contact their healthcare provider if these abnormal movements occur . …

Warnings & precautions

Do not take this medicine if: Risperidone oral solution is contraindicated in patients with a known hypersensitivity to either risperidone or paliperidone, or to any of the excipients in the risperidone formulation. Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated with paliperidone. Paliperidone is a metabolite of risperidone.

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear.

In two of four placebo-controlled trials in elderly patients with dementia-related psychosis, a higher incidence of mortality was observed in patients treated with furosemide plus risperidone when compared to patients treated with risperidone alone or with placebo plus furosemide. …

Risperidone side effects

The following are discussed in more detail in other sections of the labeling:

Increased mortality in elderly patients with dementia-related psychosis

Cerebrovascular adverse events, including stroke, in elderly patients with dementia-related psychosis

Neuroleptic malignant syndrome

Tardive dyskinesia

Metabolic Changes (Hyperglycemia and diabetes mellitus, Dyslipidemia, and Weight Gain)

Hyperprolactinemia

Orthostatic hypotension

Falls

Leukopenia, neutropenia, and agranulocytosis

Potential for cognitive and motor impairment

Seizures

Dysphagia

Priapism

Disruption of body temperature regulation

The most common adverse reactions in clinical trials (>5% and twice placebo) were parkinsonism, akathisia, dystonia, tremor, sedation, dizziness, anxiety, blurred vision, nausea, vomiting, upper abdominal pain, stomach discomfort, dyspepsia, diarrhea, salivary hypersecretion, constipation, dry mouth, increased appetite, increased weight, fatigue, rash, nasal congestion, upper respiratory tract infection, nasopharyngitis, and pharyngolaryngeal pain.

The most common adverse reactions that were associated with discontinuation from clinical trials (causing discontinuation in >1% of adults and/or >2% of pediatrics) were nausea, somnolence, sedation, vomiting, dizziness, and akathisia . …

Drug interactions

The dose of risperidone should be adjusted when used in combination with CYP2D6 enzyme inhibitors (e.g., fluoxetine, and paroxetine) and enzyme inducers (e.g., carbamazepine) . Dose adjustment is not recommended for risperidone when co-administered with ranitidine, cimetidine, amitriptyline, or erythromycin .

Co-administered Drug | Dosing Schedule | Effect on Active Moiety

(Risperidone + 9- Hydroxy-Risperidone (Ratio*) | Risperidone Dose Recommendation

Co-administered Drug | Risperidone | AUC | C

max

Enzyme (CYP2D6) Inhibitors

Fluoxetine | 20 mg/day | 2 or 3 mg twice daily | 1.4 | 1.5 | Re-evaluate dosing. Do not exceed 8 mg/day

Paroxetine | 10 mg/day | 4 mg/day | 1.3 | - | Re-evaluate dosing. Do not exceed 8 mg/day

20 mg/day | 4 mg/day | 1.6 | -

40 mg/day | 4 mg/day | 1.8 | -

Enzyme (CYP3A/ PgP inducers) Inducers

Carbamazepine | 573 ± 168 mg/day | 3 mg twice daily | 0.51 | 0.55 | Titrate dose upwards. …

About this medicine

Risperidone oral solution contains risperidone, an atypical antipsychotic belonging to the chemical class of benzisoxazole derivatives. The chemical designation is 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)- 1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one. Its molecular formula is C

23H

27FN

4O

2and its molecular weight is 410.49. The structural formula is:

Risperidone is a white to slightly beige powder. It is practically insoluble in water, freely soluble in methylene chloride, and soluble in methanol and 0.1

NHCl.

Risperidone is also available as a 1 mg/mL oral solution. Risperidone Oral Solution contains the following inactive ingredients: benzoic acid, sodium hydroxide, sorbitol solution, tartaric acid, and purified water.

How it works: The mechanism of action of risperidone in schizophrenia is unclear. The drug's therapeutic activity in schizophrenia could be mediated through a combination of dopamine Type 2 (D 2) and serotonin Type 2 (5HT 2) receptor antagonism. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID dc8c6638-f487-49df-a265-78caa93e43d8. Read the full official label on DailyMed.

Related medicines

Sertraline Escitalopram Bupropion Fluoxetine Trazodone Duloxetine Prednisone Buspirone